Eli Lilly said its experimental retatrutide beat Ozempic in weight loss and blood-sugar reductions
Eli Lilly said its experimental drug retatrutide outperformed Ozempic in an 80-week phase 3 trial involving 1,298 adults with Type 2 diabetes. Participants lost an average of 44.3 pounds on the 9-milligram dose and 47.4 pounds on the 12-milligram dose, compared with 20.9 pounds on 2-milligram Ozempic. A1C fell 2.2 percentage points versus 1.8.
More context
Eli Lilly said its experimental drug retatrutide produced greater blood-sugar reductions and more than double the weight loss of Ozempic in an 80-week phase 3 trial involving adults with Type 2 diabetes. The open-label study compared weekly 9-milligram and 12-milligram doses of retatrutide with 2 milligrams of Ozempic, the highest approved dose for Type 2 diabetes. Nearly 1,300 participants whose diabetes was not adequately controlled with metformin, with or without an SGLT2 inhibitor, took part. Participants lost an average of 44.3 pounds on 9 milligrams and 47.4 pounds on 12 milligrams, compared with 20.9 pounds on Ozempic. A1C fell 2.2 percentage points with either retatrutide dose and 1.8 with Ozempic. Lilly reported greater improvements in cholesterol, triglycerides and blood pressure. Treatment was discontinued because of side effects by 7.9% of those on 12 milligrams, versus 2.7% on Ozempic.
Was this story useful?
What was the main problem? (optional)
Reporting
- The American Journal of Managed Care — Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial | AJMC
- Demokratis — Lilly Reports Greater Weight Loss With Retatrutide Than Ozempic
- Fierce Biotech — Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown | Fierce Biotech
- BNN Bloomberg — New drug retatrutide beats Ozempic on weight loss in trial
- abc45.com — Experimental Lilly drug tops Ozempic in weight loss study
- pharmaphorum.com — Lilly's triple G overpowers Ozempic in diabetes trial | pharmaphorum
- hcplive.com — TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss | HCPLive
- everydayhealth.com — Retatrutide Helped Adults With Diabetes Lose Over 40 Pounds, More Than Double the Weight Loss of Ozempic: New Study
Verifier’s note
The reports describe Eli Lilly’s same-day phase 3 head-to-head trial, in which retatrutide outperformed semaglutide (Ozempic) on weight loss and blood-sugar control. ABC45, AJMC, pharmaphorum, HCPLive, Everyday Health, demokratis.co.id, Fierce Biotech, and BNN Bloomberg all report the central claim.